Welcome to CKB CORE's new home! Please be sure to update any bookmarks you may have.
×

Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04557059
Title A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Prostate-Specific Membrane Antigen-Positron Emission Tomography (PSMA-PET) Positive Hormone-Sensitive Prostate Cancer Participants (PRIMORDIUM)
Acronym PRIMORDIUM
Recruitment Active, not recruiting
Gender male
Phase Phase III
Variant Requirements No
Sponsors Janssen Pharmaceutica N.V., Belgium
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | ITA | ESP | DEU | BEL | AUT | AUS


No variant requirements are available.